Infants with chronic lung disease requiring medical therapy are eligible for RSV prophylaxis up to what age?

• A. <12 months
• B. <18 months
• C. <24 months
• D. <36 months

Answer: (C)

The test is about who qualifies for RSV prophylaxis in infants with chronic lung disease. For those infants who require ongoing medical therapy to manage their lung condition, protection with palivizumab is recommended through the second year of life—that is, up to 24 months of age. This reflects the continued risk of severe RSV disease in this group beyond the first year, making prophylaxis beneficial during that whole period. Once a child is older than 24 months, the proven benefit diminishes and routine prophylaxis isn’t typically recommended.